Hikma to buy Egyptian Company for Pharmaceuticals & Chemical Industries
Multinational pharmaceutical group Hikma Pharmaceuticals is set to buy Egyptian Company for Pharmaceuticals & Chemical Industries (EPCI).
Hikma will pay EGP142.4m ($22.2 m) in cash as part of the the acquisition that expects to strengthen the company's position in the Egyptian market.
The transaction will add 35 products in 46 dosage forms and strengths including 3 original cephalosporin anti-infective brands as well as enhance Hikma's portfolio in key therapeutic areas such as cephalosporin anti-infectives, central nervous system and alimentary tract.
Hikma Pharmaceuticals CEO Darwazah said the acquisition will further accelerate the growth, expanding the company's product portfolio and adding additional manufacturing capacity and technologies.
"We continue to strengthen our position as the leading regional manufacturer in MENA and to pursue other value-creating acquisition opportunities in the region," Darwazah added.
The acquisition is expected to be closed before 14 February 2013.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
ICD Research's "UnitedHealth Group Incorporated: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report" is a crucial resource for industry executives and anyone looking to access key information about "UnitedHealth Group Incorporated" ICD Research's "UnitedHealth Group Incorporated: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report" report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Reports Buy online from $125